

ASX ANNOUNCEMENT

**Allied Healthcare appoints former CSL exec Mr Peter Turvey
as a Non-Executive Director**

- **Handojo (Jet) Soedirdja retires from the board**

Perth, Australia, 18th May 2012

Allied Healthcare Group (ASX: AHZ) announced today that it has appointed Mr Peter Turvey as a non-executive Director, replacing Mr Soedirdja on the board of Allied Healthcare Group. Mr Turvey is a former CSL executive and general counsel.

"Peter's experience building a global healthcare business as well as his licensing background will be a great benefit to the Allied Healthcare Group board" said Mr Chris Catlow, Chairman of Allied Healthcare Group.

Mr Turvey worked at CSL for 19 years, initially appointed as the first corporate counsel and was appointed Company Secretary at CSL in 1998. During his time at CSL, Mr Turvey played a major role as part of the executive team that built CSL into the international company it is today. Mr Turvey was also responsible for the management and licensing of CSL's intellectual property portfolio and overseeing risk management for the Group. Mr Turvey was involved in many licensing deals, most notably the HPV vaccine Gardasil license to Merck & Co., the licensing of the Iscomatrix® adjuvant platform technology to several of the world's leading vaccine manufacturers, and establishment of the P.gingivalis vaccine technology collaboration between the CRC for Oral Health and Sanofi-Pasteur.

Mr Turvey is currently a Principal at Foursight Associates and a Non-Executive Director on the Board of listed biotechnology company Starpharma Holding Ltd as well as a Director of the industry organization Ausbiotech Ltd.

"We are excited by the experience, knowledge and networks that Peter brings to our board" said Mr Lee Rodne, MD of Allied Healthcare Group "Peter's experiences and skills are important across the three divisions of Allied"

Mr Peter Turvey will join the Allied Healthcare Group Board effective immediately. The board would like to thank Mr Soedirdja for his involvement in the company.



For more information, please contact:

Dr Julian Chick, Chief Operating Officer Allied Healthcare Group Tel: +61 3 9620 5454

Media:

Paul Dekkers

Buchan Consulting

+61 2 9237 2800

pdekkers@buchanwe.com.au

About Allied Healthcare Group Limited

Allied Healthcare Group Limited (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from Research & Development through Clinical Development as well as Sales, Marketing and Distribution.

Allied Healthcare Group is in the process of commercializing its innovative tissue engineering technology for regenerative medicine and is a major investor in Brisbane based Coridon Pty Ltd, led by Professor Ian Frazer developing next generation vaccines for global markets.

Further information on the Company can be found on www.alliedhealthcaregroup.com.au.



ABN 35 088 221 078

Level 1, 197 Adelaide Terrace
Perth Western Australia 6000

PO Box 6879 East Perth
Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E info@alliedhealthcaregroup.com.au

www.alliedhealthcaregroup.com.au